-
2
-
-
0034016343
-
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
-
(2000)
J Clin Oncol
, vol.18
, pp. 1337-1345
-
-
Van Cutsem, E.1
Findlay, M.2
Osterwalder, B.3
Kocha, W.4
Dalley, D.5
Pazdur, R.6
Cassidy, J.7
Dirix, L.8
Twelves, C.9
Allman, D.10
Seitz, J.F.11
Scholmerich, J.12
Burger, H.U.13
Verweij, J.14
-
3
-
-
0032414730
-
Capecitabine - A novel oral tumor-activated fluoropyrimidine
-
(1998)
Onkologie
, vol.21
, pp. 451-458
-
-
Frings, S.1
-
4
-
-
0034016415
-
Preferential activation of Capecitabine in tumor following oral administration to colorectal cancer patients
-
(2000)
Cancer Chemother Pharmacol
, vol.45
, pp. 291-297
-
-
Schüller, J.1
Cassidy, J.2
Dumont, E.3
Roos, B.4
Durston, S.5
Banken, L.6
Utoh, M.7
Mori, K.8
Weidekamm, E.9
Reigner, B.10
-
5
-
-
0032127244
-
Design of a novel oral fluoropyrimidine carbamate, ca-pacitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
-
(1998)
Eur J Cancer
, vol.34
, pp. 1274-1281
-
-
Miwa, M.1
Ura, M.2
Nishida, M.3
Sawada, M.4
Ishikawa, T.5
Mori, K.6
Shimma, M.7
Umeda, I.8
Ishitsuka, H.9
-
6
-
-
0000680269
-
Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer)
-
abstract
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
, pp. 1025
-
-
Lozano, R.D.1
Patt, Y.Z.2
Hassan, M.M.3
Frome, A.4
Vauthey, J.N.5
Ellis, L.M.6
Schnirer, I.7
Brown, T.D.8
Abbruzzese, J.L.9
Wolff, R.A.10
Charnsangavej, C.11
-
8
-
-
0031671094
-
A phase I and pharmacologic study of intermittent twice daily oral therapy with Capecitabine in patients with advanced and/or metastatic cancer
-
(1998)
J Clin Oncol
, vol.16
, pp. 2977-2985
-
-
MacKean, M.J.1
Planting, A.S.Th.2
Twelves, C.3
Schellens, J.H.M.4
Allman, D.5
Osterwalder, B.6
Reigner, B.7
Griffin, T.8
Kaye, S.9
Verweij, J.10
-
11
-
-
0033050165
-
A multicenter phase II study of Capecitabine in paclitaxel-refractory metastatic breast cancer
-
(1999)
J Clin Oncol
, vol.17
, pp. 485-493
-
-
Blum, J.L.1
Jones, S.E.2
Buzdar, A.U.3
LoRusso, P.M.4
Kuter, I.5
Vogel, C.6
Osterwalder, B.7
Burger, H.U.8
Brown, C.S.9
Griffin, T.10
-
12
-
-
0034778024
-
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
-
(2001)
Ann Oncol
, vol.12
, pp. 1247-1254
-
-
O'Shaughnessy, J.A.1
Blum, J.2
Moiseyenko, V.3
Jones, S.E.4
Miles, D.5
Bell, D.6
Rosso, R.7
Mauriac, L.8
Osterwalder, B.9
Burger, H.U.10
Laws, S.11
-
13
-
-
0032795880
-
Xeloda® in the treatment of metastatic breast cancer
-
(1999)
Oncology
, vol.57
, Issue.SUPPL. 1
, pp. 16-20
-
-
Blum, J.L.1
-
14
-
-
0035871538
-
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
-
(2001)
J Clin Oncol
, vol.19
, pp. 2282-2292
-
-
Hoff, P.M.1
Ansari, R.2
Batist, G.3
Cox, J.4
Kocha, W.5
Kuperminc, M.6
Maroun, J.7
Walde, D.8
Weaver, C.9
Harrison, E.10
Burger, H.U.11
Osterwalder, B.12
Wong, A.O.13
Wong, R.14
-
15
-
-
0035503151
-
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
-
(2001)
J Clin Oncol
, vol.19
, pp. 4097-4106
-
-
Van Cutsem, E.1
Twelves, C.2
Cassidy, J.3
Allman, D.4
Bajetta, E.5
Boyer, M.6
Bugat, R.7
Findlay, M.8
Frings, S.9
Jahn, M.10
McKendrick, J.11
Osterwalder, B.12
Perez-Manga, G.13
Rosso, R.14
Rougier, P.15
Schmiegel, W.H.16
Seitz, J.F.17
Thompson, P.18
Vieitez, J.M.19
Weitzel, C.20
Harper, P.21
more..
|